Business
LifeMD® Now Offering Eli Lilly and Company’s Foundayo™ (orforglipron), a New GLP-1 Pill for Weight Management
LifeMD expands its weight management program with the addition of Foundayo, offering eligible patients an oral alternative to injectable GLP-1 therapies through LillyDirect®NEW YORK, April 10, 2026 (GLOBE NEWSWIRE) -- LifeMD, Inc. (Nasdaq: LFMD), a leading provider of virtual primary care services, today announced that it is now offering Foundayo™ (orforglipron) to eligible patients through its weight management program. Foundayo, developed by Eli Lilly and Company, is a once daily oral treatmen
About this update from Lifemd, Inc.
[{"type":"image","alt":"LifeMD, Inc.","displaySize":"","headline":null,"caption":"LifeMD, Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":300,"url":"https://media.zenfs.com/en/globenewswire.com/50005343bf87c0ac412a1713ee8f08dc"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/tMNNtDux7OX5hiGLq8mc0Q--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTQyMA--/https://media.zenfs.com/en/globenewswire.com/50005343bf87c0ac412a1713ee8f08dc","width":300,"height":300}},"lazy":false},{"type":"text","content":"LifeMD expands its weight management program with the addition of Foundayo, offering eligible patients an oral alternative to injectable GLP-1 therapies through LillyDirect®","length":173,"tagName":"p"},{"type":"text","content":"NEW YORK, April 10, 2026 (GLOBE NEWSWIRE) -- LifeMD, Inc. (Nasdaq: LFMD), a leading provider of virtual primary care services, today announced that it is now offering Foundayo™ (orforglipron) to eligible patients through its weight management program. Foundayo, developed by Eli Lilly and Company, is a once daily oral treatment for adults with obesity or overweight with weight-related medical problems.","length":404,"tagName":"p"},{"type":"text","content":"Foundayo is available to eligible LifeMD patients through the Company’s integration with LillyDirect®, which enables prescriptions to be fulfilled and shipped directly to patients. The starting self-pay price for Foundayo is $149 per month for the initial dosage. Patients with eligible commercial insurance may pay as little as $25 per month through a Lilly savings card, and Medicare coverage is anticipated to begin July 2026. The FDA approved Foundayo on April 1, 2026, making it the second oral GLP-1 therapy approved for weight management.","length":545,"tagName":"p"},{"type":"text","content":"“The approval of Foundayo is another landmark moment in the treatment of obesity. Patients have access to a once-daily GLP-1 pill that may fit seamlessly into their lives,” said Justin Schreiber, Chairman and Chief Executive Officer of LifeMD. “By working with LillyDirect, we are able to offer eligible patients streamlined access to this therapy at an accessible price point. LifeMD remains dedicated to expanding access to high-quality, affordable weight management care, and the addition of Foundayo to our platform furthers that commitment.”","length":546,"tagName":"...